Loading...
•
Mar 31, 2021
Edwards Lifesciences Q1 2021 Earnings Report
Edwards Lifesciences reported first quarter results with sales growth and EPS exceeding expectations.
Key Takeaways
Edwards Lifesciences reported sales of $1.2 billion, an 8% increase over the prior year, with underlying sales growing by 5%. EPS reached $0.54, surpassing expectations. The company is confident in its 2021 outlook and raised its adjusted EPS guidance.
Sales grew 8 percent to $1.2 billion; underlying sales grew 5 percent
TAVR sales grew 7 percent; underlying sales grew 4 percent
EPS of $0.54 exceeded expectations
Adjusted EPS guidance of $2.07 to $2.27 increased $0.07
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences anticipates total sales between $1.25 and $1.33 billion for the second quarter of 2021, with adjusted EPS projected to be $0.54 to $0.60. Full year 2021 sales guidance remains at $4.9 to $5.3 billion, and adjusted earnings per share are raised to $2.07 to $2.27.
Positive Outlook
- Full year 2021 sales guidance for Edwards remains at $4.9 to $5.3 billion.
- Company is raising full year 2021 adjusted earnings per share to $2.07 to $2.27 from $2.00 to $2.20.
- Company projects total sales to be between $1.25 and $1.33 billion for the second quarter of 2021.
- Adjusted EPS of $0.54 to $0.60 for the second quarter of 2021.
- Confident in long-term patient-focused strategy and innovation pipeline.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...